Dublin, June 28, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Molecular Cytogenetics - Global Strategic Business Report" report to their offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Molecular Cytogenetics in US$ Thousand by the following Technologies: Fluorescence In Situ Hybridization, Array-based Technology.
The report profiles 27 companies including many key and niche players such as
- Abbott Molecular, Inc. (US)
- Agilent Technologies, Inc. (US)
- Affymetrix, Inc. (US)
- Applied Spectral Imaging (US)
- Biological Industries (Israel)
- Bio-Rad Laboratories, Inc. (US)
- CytoTest, Inc. (US)
- Cytognomix, Inc. (Canada)
- Illumina, Inc. (US)
- Leica Biosystems Nussloch GmbH (Germany)
- Oxford Gene Technology (UK)
- PerkinElmer, Inc. (US)
- Roche NimbleGen, Inc. (US)
- SciGene Corporation (US)
- Thermo Fisher Scientific, Inc. (US)
Key Topics Covered:
1. INDUSTRY OVERVIEW
- Advanced Molecular Biology Techniques Broaden the Scope of Cytogenetics
- Major Growth Drivers
- Market Outlook
- Nucleic Acid Diagnostics Market
- An Overview
- Molecular Cytogenetics Greatly Benefit Cancer Prognosis
- Diverse Applications of FISH Technology in Oncology
- Opportunity Indicators: Global Cancer Incidence on the Rise
- Increasing Significance of Cytogenetic Analysis in Genetic Disease Diagnosis
- Array-based Technologies to Drive Significant Market Growth
- Transition from FISH to Array Based Technologies: A Major Trend
- Array-based CGH to Emerge as First Line Test for Clinical Diagnosis of Chromosomal Anomalies
- Molecular Cytogenetics Find Increasing Penetration in Clinical Pathological Testing
- Enhanced AP LIS a Must to Keep Pace with Advancing Molecular Cytogenetic Testing
- Impact of Shifting Focus of Biopharmaceuticals from Research to Development on Microarray Technology
- Next-Gen Sequencing to Challenge Microarray Technology in the Distant Future
- Technological Innovations Set to Drive the Market
- Role of Molecular Cytogenetics in Personalized Medicine
- Improving Healthcare Expenditure Turbo Charges Demand
2. TECHNOLOGY OVERVIEW
3. PRODUCT LAUNCHES/APPROVALS
- NeoGenomics Introduces NeoSITE Cervical assay to FISH Testing Menu
- Oxford Gene Technology Expands Cytocell FISH Probe Portfolio
- Applied Spectral Imaging Receives Approval for GenASIs HiPath Platform
- Agilent Technologies Introduces OneSeq
- Leica Biosystems and Affymetrix Launch ViewRNA eZ Assays on BOND RX Platform
- Affymetrix and BioDiscovery Launch Cancer Research Software
- AKESOgen Launches Cytogenomics Microarray Test
- Oxford Gene Technology Launches CytoSure Consortium Cancer + SNP array
4. RECENT INDUSTRY ACTIVITY
- Eurofins Scientific to Acquire Stake in Emory Genetics Laboratory
- ESPERITE Acquires Inkaryo
- Medivo Collaborates with NeoGenomics for Data Analytics
- Affymetrix Enters into Agreement with CollabRx
- Thermo Fisher Scientific Completes Acquisition of Life Technologies
- Applied Spectral Imaging Signs Distribution Partnership with Biocare
- Applied Spectral Imaging and BioDot Enter Into Marketing Agreement
- Cancer Genetics Italia Enters into Distribution Agreement with Nikon Instruments S.p.A.
- Applied Spectral Imaging Enters Into Agreement with WaveSense
- Oxford Gene Technology Signs License Agreement with CCMC
5. FOCUS ON SELECT PLAYERS
6. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 27 (including Divisions/Subsidiaries 28)
- The United States (20)
- Canada (1)
- Europe (6)
- - Germany (2)
- - The United Kingdom (1)
- - Rest of Europe (3)
- Asia-Pacific (Excluding Japan) (1)
For more information visit http://www.researchandmarkets.com/research/89lmqw/molecular